The FDA recently reevaluated accelerated approvals for 35 oncology indications for anti–programmed death ligand 1 antibodies, revealing that for 10 indications, the required trials did not end up confirming benefit and yet their marketing authorization continued.
No takes yet. Share an insight, caveat, or question.
Beaver et al. (2021) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: